4.7 Article

Complete tumor necrosis after neoadjuvant chemotherapy defines good responders in patients with Ewing sarcoma

Related references

Note: Only part of the references are listed.
Article Oncology

Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report

Patrick J. Leavey et al.

Summary: The study aimed to test whether the addition of VTC to interval compressed chemotherapy improved survival outcomes for Ewing sarcoma patients. The results showed no difference in survival outcomes between the two groups, with age and primary site not affecting the EFS event risk, but age >= 18 years being associated with increased risk of death at 5 years.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Review Oncology

Prognostic factors for survival in Ewing sarcoma: A systematic review

S. E. Bosma et al.

SURGICAL ONCOLOGY-OXFORD (2018)

Review Oncology

Ewing Sarcoma: Current Management and Future Approaches Through Collaboration

Nathalie Gaspar et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Article Orthopedics

Osteosarcoma, chondrosarcoma, and Ewing's sarcoma

Timothy A. Damron et al.

CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2007)

Review Oncology

Current treatment for Ewing's sarcoma

MM Thacker et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2005)